The Bottom Line

Over 80% of Stevens-Johnson Syndrome (SJS) cases are caused by specific medications. Knowing which drugs carry the highest risk — sulfonamide antibiotics, certain anticonvulsants (carbamazepine, lamotrigine, phenytoin), allopurinol, and some NSAIDs — can help you and your doctor make informed prescribing decisions. Genetic testing is available for some high-risk drug-gene combinations and can prevent SJS before it starts. If you've ever had SJS, permanent avoidance of the causative drug is essential.

Which Medications Cause Stevens-Johnson Syndrome?

SJS is primarily a drug-induced condition. The most commonly implicated medications, supported by large epidemiological studies, include:

Highest-risk medications:

  • Allopurinol: Used for gout. One of the most common SJS triggers worldwide. Risk is dramatically higher (80-100 fold) in carriers of the HLA-B*5801 gene variant, which is prevalent in Southeast Asian (6-8%), African American (3-4%), and Korean (12%) populations.
  • Sulfonamide antibiotics: Trimethoprim-sulfamethoxazole (Bactrim/Septra) is the most commonly implicated antibiotic. Risk is highest in the first 2 months of use.
  • Aromatic anticonvulsants: Carbamazepine (Tegretol), phenytoin (Dilantin), phenobarbital, and lamotrigine (Lamictal). Risk is highest during the first 8 weeks of therapy. Lamotrigine risk increases with rapid dose escalation (which is why slow titration is mandatory).
  • Oxicam NSAIDs: Piroxicam carries the highest NSAID risk. Other NSAIDs (ibuprofen, naproxen) have very low but non-zero risk.
  • Nevirapine: An HIV antiretroviral with well-documented SJS risk.

Moderate-risk medications: Aminopenicillins (amoxicillin), cephalosporins, fluoroquinolones, and some antifungals.

Timeline: SJS most commonly develops 7-21 days after starting the causative drug (the sensitization period). For drugs taken previously without issue, SJS can still develop — prior tolerance does not guarantee future safety if the drug is restarted after a gap.

Understanding Your Risk Factors

Genetic factors (most important):

  • HLA-B*5801: Dramatically increases allopurinol SJS risk. The FDA recommends testing before prescribing allopurinol, especially in at-risk ethnic groups.
  • HLA-B*1502: Increases carbamazepine and phenytoin SJS risk significantly in Southeast Asian populations. FDA-mandated testing before prescribing carbamazepine to patients of Southeast Asian ancestry.
  • HLA-A*3101: Increases carbamazepine SJS risk in European and Japanese populations.

Other risk factors:

  • HIV/AIDS (100-fold increased risk due to immune dysregulation and frequent medication exposure)
  • Immunosuppression (organ transplant recipients, cancer patients)
  • Previous history of SJS (dramatically increased risk of recurrence if re-exposed)
  • Systemic lupus erythematosus
  • Slow acetylator status (affects drug metabolism)

How to Reduce Your SJS Risk

Before starting high-risk medications:

  • Ask your doctor about genetic testing if you're being prescribed allopurinol (HLA-B*5801) or carbamazepine (HLA-B*1502 if Southeast Asian ancestry)
  • Discuss your family and personal history of drug reactions
  • Inform your doctor of all current medications (drug interactions can increase risk)
  • For lamotrigine: insist on the recommended slow dose escalation schedule — rapid dose increases significantly raise SJS risk

During the high-risk window (first 8 weeks of a new medication):

  • Be alert for warning signs: fever, sore throat, painful skin, mouth sores, eye irritation
  • If you develop ANY combination of fever + skin pain + mucosal symptoms after starting a new drug, stop the medication and seek emergency care immediately
  • Do not dismiss early symptoms as a "cold" or "allergies" — the prodromal phase of SJS mimics viral illness

If you've had SJS before:

  • The causative drug must be permanently documented in your medical records, pharmacy profile, and an allergy alert bracelet
  • Related drugs in the same chemical class may need to be avoided (discuss with an allergist)
  • Inform EVERY healthcare provider about your SJS history before any new medication is prescribed
  • Carry a drug allergy card listing your specific triggers

When to Seek Emergency Care

Go to the emergency department immediately if you develop fever plus painful or tender skin (even before blisters appear), mouth sores or difficulty swallowing after starting a new medication, red or painful eyes with skin symptoms, or any blistering or peeling of the skin. Time is critical — the earlier the offending drug is stopped and supportive care begins, the better the outcome. Do NOT wait to see a dermatologist first — SJS requires emergency hospitalization.

Frequently Asked Questions

Can I take ibuprofen or acetaminophen if I've had SJS from another drug?

If your SJS was caused by a specific drug (e.g., Bactrim, carbamazepine, allopurinol), you can generally take unrelated medications safely. However, if your SJS was caused by an NSAID, all NSAIDs in that class should be avoided — your allergist can advise which specific alternatives are safe. Acetaminophen (Tylenol) is not associated with SJS and is generally considered safe regardless of your SJS history.

Should my family members be tested for SJS risk genes?

If you carry a high-risk HLA allele (HLA-B*5801 or HLA-B*1502), first-degree relatives (parents, siblings, children) have a 50% chance of carrying the same allele. Testing is recommended for relatives if they may need the same medication. This is especially relevant for allopurinol (gout runs in families) and anticonvulsants (epilepsy may have genetic components).

How common is SJS really?

SJS affects approximately 1-6 people per million per year in the general population. While rare, the severity makes it critically important. Certain medications in certain populations carry dramatically higher individual risk — for example, the risk of allopurinol SJS in an HLA-B*5801 carrier may be 1 in 200 rather than 1 in a million. This is why genetic testing matters for high-risk drug-gene combinations.

What is the long-term outlook after surviving SJS?

Most SJS survivors recover fully, but long-term complications are common: dry eyes and chronic eye problems (up to 50% of survivors), skin pigmentation changes, scarring of mucous membranes, nail abnormalities, and significant psychological impact (PTSD, depression, anxiety). Regular follow-up with ophthalmology, dermatology, and mental health support is important for comprehensive recovery.

References

  1. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
  2. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs (EuroSCAR study). J Invest Dermatol. 2008;128(1):35-44.
  3. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153-158.
  4. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.

Trusted Resources

Prevention through genetic testing and drug awareness is the most powerful tool against SJS. Know your risk medications and act on early warning signs.